Skip to main content
SP5007,674.37+0.43%DOW53,277.01+0.98%NASDAQ26,180.46+0.43%BTC$77,812.00+5.53%ETH$2,513.75+7.22%GOLD$4,661.60+1.97%OIL$86.64-0.22%
Smart Investors Daily
Sign InSign Up Free
eFFECTOR Therapeutics, Inc. logo

OTC · EFTR

eFFECTOR Therapeutics, Inc.

Healthcare · Biotechnology

$0.00

Up+$0.00 (+0.00%)

Updated Aug 23, 2026, 12:06 AM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
941
P/E ratio
-0
Dividend yield
0.00%
52-week range
$0.00 – $0.01
Volume
112.14K
Avg. volume
3.43K

Price performance

EFTR price history

1M range · 5 trading sessions · Daily adjusted prices

EFTR closed at $0.00 after 5 trading sessions, up 50.00% for the selected period.

Last close
$0.00
Period change
+50.00%
Period low
$0.00
Period high
$0.00
Daily close
View OHLC price history
EFTR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 21, 2026$0.0003$0.0003$0.0003$0.0003112.14K
Aug 18, 2026$0.0008$0.0008$0.0008$0.0008225
Aug 14, 2026$0.0002$0.0002$0.0002$0.0002127
Aug 13, 2026$0.0002$0.0002$0.0002$0.0002186
Jul 29, 2026$0.0002$0.0002$0.0002$0.0002181

Latest EFTR news

The latest Smart Investors Daily articles mentioning EFTR.

Stock researchCompany · Overview

EFTR research

Overview

Company profile and research snapshot.

Company profile

EFFECTOR THERAPUTCS INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$5.50
Implied upside
—
Analysts
—
EFTR recent ratings
DateFirmRatingTarget
Mar 28, 2024HC Wainwright & Co.Buy—
Feb 6, 2024HC Wainwright & Co.Buy—
Nov 14, 2023HC Wainwright & Co.Buy—
Aug 24, 2023HC Wainwright & Co.Buy—
May 26, 2023StifelBuy—
Open full forecast

News briefing

No generated briefing is available yet.

defenseworld.net · Nov 22, 2025

eFFECTOR Therapeutics (NASDAQ:EFTR) & NexImmune (NASDAQ:NEXI) Critical Contrast

Profitability This table compares eFFECTOR Therapeutics and NexImmune's net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets eFFECTOR Therapeutics N/A N/A N/A NexImmune N/A -534.32% -213.72% Institutional and Insider Ownership 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. Comparatively, 9.9% of NexImmune shares are owned

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By